Cybrexa Therapeutics reports that Arthur DeCillis, MD, has joined the company as Acting Chief Medical Officer.
Dr. DeCillis will be responsible for the development of the first-in-human study of Cybrexa’s lead program, CBX-12 (alphalexTM-exatecan), and early and late stage clinical programs for the Cybrexa portfolio.
Dr. DeCillis brings over 20 years of experience in pharma and biotech, having worked on multiple oncology products with over $1 billion in sales.